Biological evaluation and structure modification of (S)-3-aminopyrrolidine derivatives

Abstract

With our interest in (S)-3-aminopyrrolidine derivatives, we further screened inhibition activities of three hit compounds on many other kinases with the results demonstrating that this series of compounds shows better anticancer activities, which might result from the main block of PI3K/Akt signaling pathway and the inhibition of Abelson murine leukemia viral oncogene homolog(ABL) kinase, as well as some epidermal growth factors. Further structure modification demonstrates that benzylsulfonyl group is the necessary functional group contributing to the biological activity that will be helpful to guiding us to optimize these (S)-3-aminopyrrolidine derivatives.

Keywords

(S)-3-Aminopyrrolidine / Biological evaluation / Structure modification

References

[1] Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, Lydon N B, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers C L. N. Engl. J. Med., 2001, 344: 1031.

[2] Liao J J L. J. Med. Chem., 2007, 50: 409.

[3] Morphy R. J. Med. Chem., 2010, 53: 1413.

[4] Golas J M, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli D H, Boschelli F. Cancer Res., 2003, 63: 375.

[5] Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T. Blood, 2005, 106: 3948.

[6] Lockton J A, Smethurst D, Macpherson M, Tootell R, Marshall A L, Clack G, Gallagher N J. J. Clin. Oncol., 2005, 23: 223s.

[7] Daub H, Specht K, Ullrich A. Nat. Rev. Drug Discovery, 2004, 3: 1001.

[8] Shah N P, Nicoll J M, Nagar B, Gorre M E, Paquette R L, Kuriyan J, Sawyers C L. Cancer Cell, 2002, 2: 117.

[9] Weisberg E, Griffin J D. Drug Resist. Updates, 2001, 4: 22.

[10] Weisberg E, Griffin J D. Blood, 2000, 95: 3498.

[11] Engelman J A, Zejnullahu K, Mitsudomi T, Song Y C, Hyland C, Park J O, Lindeman N, Gale C M, Zhao X J, Christensen J, Kosaka T, Holmes A J, Rogers A M, Cappuzzo F, Mok T, Lee C, Johnson B E, Cantley L C, Janne P A. Science, 2007, 316: 1039.

[12] Huo X, Zhang Q, Liu Y. Chem. Res. Chinese Universities, 2010, 26(3): 409.

[13] Burchert A, Wang Y, Cai D, Bubnoff N V, Paschka P, Muller-Brusselbach S, Ottmann O G, Duyster J, Hochhaus A, Neubauer A. Leukemia, 2005, 19: 1774.

[14] Apsel B, Blair J A, Gonzalez B, Nazif T M, Feldman M E, Aizenstein B, Hoffman R, Williams R L, Shokat K M, Knight Z A. Nat. Chem. Biol., 2008, 4: 691.

[15] Peng H, Huang N, Qi J, Xie P, Xu C, Wang J X, Yang C Z. Bioorg. Med. Chem. Lett., 2003, 13: 3693.

[16] Zhang C L, Tan C Y, Zu X Y, Zhai X, Liu F, Chu B Z, Ma X H, Chen Y Z, Gong P, Jiang Y Y. Eur. J. Med. Chem., 2011, 46: 1404.

[17] Yano S, Nishioka Y, Goto H, Sone S. Assay Drug Dev. Technol., 2007, 5: 75.

[18] Konecny G E, Pegram M D, Venkatesan N, Finn R, Yang G R, Rahmeh M, Untch M, Rusnak D W, Spehar G, Mullin R J, Keith B R, Gilmer T M, Berger M, Podratz K C, Slamon D J. Cancer Sci., 2003, 94: 479.

[19] Liu H C, Dong A J, Gao C M, Tan C Y, Liu H X, Zu X Y, Jiang Y Y. Cancer Res., 2006, 66: 1630.

[20] Baki A, Bielik A, Molnar L, Szendrei G, Keseru G M. Bioorg. Med. Chem., 2008, 16: 100.